Abatacept Infusion for COVID-19
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests if using abatacept with usual treatment helps hospitalized COVID-19 patients recover better by calming their immune system.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on certain immune-modulating drugs, you may need to discuss this with the trial team, as some exclusions apply.
How does the drug abatacept differ from other COVID-19 treatments?
Abatacept is unique because it is a biologic drug that modulates the immune system by inhibiting T cell activation, which is different from many COVID-19 treatments that focus on antiviral effects. It is administered through infusion, which is less common for COVID-19 therapies that are often oral or injectable.12345
What data supports the effectiveness of the drug abatacept for treating COVID-19?
Who Is on the Research Team?
Cavan Reilly, PhD
Principal Investigator
University of Minnesota
Christina Barkauskas, MD
Principal Investigator
Duke University
Are You a Good Fit for This Trial?
This trial is for hospitalized COVID-19 patients who recently started low flow oxygen therapy and are already taking an immune modulator like corticosteroids. They must have evidence of pneumonia caused by COVID-19 but not be on high levels of oxygen support or other advanced respiratory assistance. Excluded are those with severe immune deficiencies, active serious infections, certain blood disorders, recent live vaccines, pregnancy, breastfeeding, or specific treatments that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either IV abatacept infusion or placebo combined with standard of care to improve recovery from COVID-19
Follow-up
Participants are monitored for sustained recovery, pulmonary outcomes, and all-cause mortality
What Are the Treatments Tested in This Trial?
Interventions
- abatacept
- Abatacept
- Placebo
- Placebo group
abatacept is already approved in European Union, United States, Canada, Japan, Switzerland for the following indications:
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Minnesota
Lead Sponsor